Homburger advised BioVersys, a clinical-stage biopharmaceutical company domiciled in Basel, on all aspects of its Initial Public Offering (IPO). The Initial Public Offer The IPO was launched on SIX Swiss Exchange, comprising a primary
Tags :BioVersys
On January 5, 2023, BioVersys announced that the AMR Action Fund has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 million. The Swiss pharma company represents the first European-based
The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends
